Compare RENX & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | ALZN |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | 38 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.1M |
| IPO Year | N/A | 2021 |
| Metric | RENX | ALZN |
|---|---|---|
| Price | $2.86 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 5.5M | 193.1K |
| Earning Date | 05-22-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.51 |
| 52 Week High | $3.48 | $8.22 |
| Indicator | RENX | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 71.88 | 34.76 |
| Support Level | $0.12 | N/A |
| Resistance Level | $3.48 | $2.59 |
| Average True Range (ATR) | 0.41 | 0.15 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 79.92 | 18.35 |
RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.